| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Fusion Pharmaceuticals (NASDAQ:FUSN) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Fusion Pharmaceuticals missed estimated earnings by -15.0%, reporting an EPS of $-0.39 versus an estimate of $-0.34.
Revenue was down $140 thousand from the same period last year.
Last quarter the company beat on EPS by $0.15 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Fusion Pharmaceuticals's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.40 | -0.39 | -0.32 | -0.56 |
| EPS Actual | -0.25 | -0.38 | -0.45 | -0.55 |
| Revenue Estimate | 110K | 80K | 8.57M | 20K |
| Revenue Actual | 2.01M | 34K | 28K | 140K |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for Fusion Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: FUSN
